|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Celgene plunged to another four-year low Monday on a report that an executive in charge of business development quietly retired in mid-April.
Celgene Corporation (NASDAQ: CELG) is an integrated biotechnology company that develops and sells therapies for the treatment of oncology and inflammatory diseases through gene and protein regulation. Celgene is most known for its blockbuster drug Revlimid, which treats multiple myeloma. Despite significant growth in this disease around the world, Celgene shows too much reliance on a single drug, and the company undertook a number of acquisitions to diversify its drug portfolio with immuno-oncology therapies.
Learn about Celgene Corporation and its key financial ratios, such as the debt-to-equity (D/E) ratio, operating margin and return on invested capital (ROIC).
Stock Monitor: Juno Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 23, 2018 / Active-Investors.com has just released a free research report on Celgene Corp. (NASDAQ: CELG ). If ...
Celgene Corporation today announced that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to the previously announced tender offer by Celgene’s wholly owned subsidiary, Blue Magpie Corporation, for all issued and outstanding shares of common stock of Juno Therapeutics, Inc.
Although Juno Therapeutics' (JUNO) product portfolio lacks revenue figures, the company's most advanced pipeline candidates, JCAR017 and JCAR014, might still drive the stock in Q4.
This year could be big for biotech mergers after Celgene and Sanofi, in a few days, spent $25 billion for three companies.
Moody's Investors Service ("Moody's") assigned a rating of Baa2 to the new senior unsecured note issuance of Celgene Corporation ("Celgene"). There are no changes to Celgene's existing ...
Vertex Pharmaceuticals, Amgen and Johnson and Johnson were among the big movers in the biotech and pharmaceutical sectors.
Celgene paid top dollar for Juno Therapeutics last month, but the biotech heavyweight may end up with buyer's remorse. Here's why.
NEW YORK, NY / ACCESSWIRE / February 2, 2018 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a boutique securities firm headquartered at the Empire State Building in New ...